{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:49:26Z","timestamp":1784173766503,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving. However adequate patient selection criteria for SABR in patients with LAPC are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective institutional database collected data of patients with LAPC treated with chemotherapy, mainly FOLFIRINOX, followed by SABR, which was delivered using magnetic resonance guided radiotherapy, 40 Gy in 5 fractions within two weeks. Primary endpoint was overall survival (OS). Cox regression analyses were performed to identify predictors for OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 74 patients were included, median age 66 years, 45.9% had a KPS score of \u226590. Median OS was 19.6 months from diagnosis and 12.1 months from start of SABR. Local control was 90% at one year. Multivariable Cox regression analyses identified KPS \u226590, age &amp;lt;70, and absence of pain prior to SABR as independent favorable predictors for OS. The rate of grade \u22653 fatigue and late gastro-intestinal toxicity was 2.7%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SABR is a well-tolerated treatment in patients with unresectable LAPC following chemotherapy, with better outcomes when applied in patients with higher performance score, age &amp;lt;70 years and absence of pain. Future randomized trials will have to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1149961","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:24:35Z","timestamp":1685510675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy -\u00a0a single center prospective cohort"],"prefix":"10.3389","volume":"13","author":[{"given":"D.","family":"Doppenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"Lagerwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"van Dieren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"van der Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"van Tienhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Versteijne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M. E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.1113","article-title":"Therapeutic advances in localized pancreatic cancer","volume":"151","author":"Tsai","year":"2016","journal-title":"JAMA Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024068","article-title":"Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.3390\/cancers13174326","article-title":"Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-a systematic review and meta-analysis","volume":"13","author":"Damm","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","article-title":"Pancreatic adenocarcinoma, version 1.2022, NCCN clinical practice guidelines in oncology national comprehensive cancer network: national comprehensive cancer network","author":"Tempero","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30856","article-title":"Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review","volume":"123","author":"de Geus","year":"2017","journal-title":"Cancer"},{"key":"B9","first-page":"619","article-title":"ACR appropriateness Criteria(R) borderline and unresectable pancreas cancer","volume":"30","author":"Small","year":"2016","journal-title":"Oncol (Williston Park)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.017376","article-title":"Locally advanced unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline summary","volume":"13","author":"Balaban","year":"2017","journal-title":"J Oncol Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2017.02.005","article-title":"Integration of stereotactic body radiation therapy into the multidisciplinary management of pancreatic cancer","volume":"27","author":"Rosati","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1754-4505.2009.00088.x","article-title":"Karnofsky performance status scale","volume":"29","author":"Friendlander","year":"2009","journal-title":"Spec Care Dentist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.radonc.2018.11.019","article-title":"Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy","volume":"132","author":"Bohoudi","year":"2019","journal-title":"Radiother Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B16","unstructured":"Common terminology criteria for adverse events (CTCAE) v5.0 Cancer.gov2017"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern cooperative oncology group trial","volume":"29","author":"Loehrer S.R.","year":"2011","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer","volume":"19","author":"Chauffert","year":"2008","journal-title":"Definitive results 2000-01 FFCD\/SFRO study Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5373-2","article-title":"Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer","volume":"23","author":"Rombouts","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.888462","article-title":"Induction chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy for inoperable pancreas cancer","volume":"12","author":"Chuong","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.07.053","article-title":"Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma","volume":"152","author":"Toesca","year":"2020","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2019.04.020","article-title":"The role of biological dose-escalation for pancreatic cancer","volume":"18","author":"Bruynzeel","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2011.021","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2021.09.004","article-title":"Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma","volume":"24","author":"Daamen","year":"2022","journal-title":"Hpb"},{"key":"B31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/0284186X.2017.1400692","article-title":"Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the academic medical center (AMC) experience","volume":"57","author":"Ebrahimi","year":"2018","journal-title":"Acta Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2021.04.002","article-title":"The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: is it time for change","volume":"28","author":"Ryckman","year":"2021","journal-title":"Clin Transl Rad Onco"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1149961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:24:50Z","timestamp":1685510690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1149961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":32,"alternative-id":["10.3389\/fonc.2023.1149961"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1149961","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"1149961"}}